For ever odd wrote: » 100 ema is 21.75 on daily, and would be roughly half of the gap down on jan 15(?). Short term target would be around that area for me. EDIT; target hit, 20% rise today. Nice one Robert!
RobertKK wrote: » Thanks. and you showed how good you are. Closed at $21.71, which is around where you said. The few on stocktwits who said they were shorting well below that could have done with your advice...
For ever odd wrote: » Hmmm, there are guys who bought this at €11, the likes of yourself that are in at €16,and the likes of myself who made a fast buck today at €18ish...And then there is the guys to come. This has the perfect hallmarks of a pump and dump (great for you if it is) I can just imagine what's been said, 100% since Jan, 20% today, this is going to rocket... €100+ etc etc. Tomorrow should tell a tale, whether today was the start of it, or whether today was all the early birds unloading /profit taking. Just an example of who's knocking around.
RobertKK wrote: » That short term call you made two days ago was really spot on.
ixus wrote: » Not to forget end of Quarter.
Augeo wrote: » Hugo Boss AG €54.69, dust has settled after notification of 2016 profits being lower than expected in February and subsequently the CEO stepping down a week later. €3.62 dividend Payable Date & Record Date 20May2016, 6.6% ish. Decent stock imo for the short term (1 to 3 years)
For ever odd wrote: » Alot of luxury brands have issued profit warnings for 2016, it's not just Hugo Boss, the sector is rattled. The old adage 'Sell the first profit warning, Buy the third' springs to mind. If the opportunity arose I would consider buying Hugo Boss at €41 and if lucky €32 for a long term hold (20+ years). As of now, it is rising from its feb low, with decreasing volume.
Sabre Man wrote: » I don't think they will have a problem selling the cars. ..........
RobertKK wrote: » Bought GNCA at $5.84 at 7.50pm, it closed at $7.74 at 9pm, they rose strongly after Cowen gave them a price target of $40 after results of a trial on herpes came out earlier in the day. Adam Feuerstein then gave his opinion on the biotech stock's trial results which caused the stock to slump to below $6.60 in after hours trading after it has risen to over $8.30 before his tweets. Then it rebounded to it's current price in AH at $7.54. Not sure if I should have sold earlier, but tomorrow should be interesting either way. Whoever thought herpes could be such fun :pac:
spaceman902 wrote: » I have a nice little trade going with SYN at the minute, bought in at 1.92, currently trading at 2.50. It's just broken above the 200 day MA, and the price has just passed an inverse head and shoulders on the 1 day chart. I have been reading that an exit at bout 2.66 would be wise with this formation, and I think I'll take some profits when this happens. Any chartists on the thread that might have an opinion? Thanks in advance!
For ever odd wrote: » Bought the DAX at 9500, S&P 1900 holding for now. Just taking on the level, also divergence on daily chart.
RobertKK wrote: » Biotech on fire again after it had been as popular as zika virus for several months now. Yesterday biotech ETFs IBB up 6% and XBI up 7%. Some massive gains for individual biotech stocks Still holding my SRPT shares but plan on selling most before 23rd April given a binary event looms. Up 19% yesterday as it broke through the 21.70s resistance area to close at $23.30. Technically the charts shows the next resistance level is at $36, here's hoping the run continues and a gap fill.
All markets are prone to bubbles, where investors get overenthusiastic about a particular asset. The tricky bit is spotting them before they pop. Analysts at UBS have found a way to crunch the numbers to do just that. At the start of the year they said US health stocks looked expensive and shares in global energy firms were cheap – and they were right. The energy sector no longer stands out as a crowded sell in the US and developed Europe, but remains a crowded sell for Asia ex-Japan. The over-bought pressure in the US and Asia ex-Japan Healthcare sector has also released to a certain extent, albeit for the US all three indicators are still relatively high compared with historical levels. This time around the expensive shares are in the European tech industry, which are soaring after recommendations to buy from investment banks. Meanwhile, stocks in Asian banks look cheap, according to UBS: New sectors that stand out European IT emerged as the crowded-bought sector, driven mainly by the Semiconductor names. In Asia ex-Japan, the Financials sector continues to deteriorate, reflecting ongoing concerns around Asia’s credit cycle.